Similarly, genomic characterization of the prostate tumor may help select the best radiosensitizing drug, such as DNA repair inhibitors or immunotherapy in DDR-deficient tumors, or AKT pathway inhibitors in PTEN mutated tumors. Here, AKT1 is linked to prostate neoplasm.